Isosorbide dinitrate tablets

The main pharmacological action of isosorbide dinitrate (ISDN) is to relax vascular smooth muscle. ISDN is metabolized in the body to produce isosorbide mononitrate (ISMN), which releases nitric oxide (NO). NO is the same as endothelial relaxing factor, activating guanylate cyclase and increasing cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, and having a stronger dilating effect on veins. Venous dilation causes blood to accumulate in the periphery, reducing the amount of blood returning to the heart, and reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arterial dilation reduces peripheral vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Coronary artery dilation increases coronary perfusion. The overall effect is to reduce myocardial oxygen consumption, increase oxygen supply, and relieve angina pectoris.

The main ingredient is isosorbide dinitrate. Its chemical name is 1,4,3,6-dianhydro-D-sorbitol dinitrate.

This product is white or off-white powder.

Long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; combined with digitalis and/or diuretics to treat chronic congestive heart failure; treatment of pulmonary hypertension.

Oral: To prevent angina pectoris, 5-10 mg once, 2-3 times a day, total daily amount 10-30 mg. Due to different individual reactions, the dose needs to be adjusted individually. Sublingual administration: 5 mg once, to relieve symptoms.

In the early stage of medication, nitrate-induced vasodilatory headache may occur, as well as facial flushing, dizziness, orthostatic hypotension and reflex tachycardia. Occasionally, blood pressure may be significantly reduced, bradycardia and angina pectoris may be aggravated, and collapse and syncope may rarely occur.

Acute circulatory failure (shock, circulatory collapse); severe hypotension (systolic blood pressure 90 mmHg); acute myocardial infarction with low filling pressures (unless under continuous hemodynamic monitoring); hypertrophic obstructive cardiomyopathy; constrictive pericarditis or cardiac tamponade; severe anaemia; glaucoma; increased intracranial pressure; primary pulmonary hypertension; allergy to nitro compounds.

Precautions for children: All studies on this type of drug were conducted in adults. There is no data comparing the use of drugs in children and adults, so it is not recommended for use in children. Precautions for pregnancy and lactation: No toxic effects on embryos were observed in animal experiments, and it is not clear whether ISMN is excreted through breast milk. However, due to the lack of experience in the use of drugs in pregnant and lactating women, it should be used with caution. Precautions for the elderly: Elderly patients may be more sensitive to this type of drug and are more likely to experience reactions such as dizziness.

The combination of this drug with other vasodilators, calcium antagonists, beta-receptor blockers, antihypertensive drugs, tricyclic antidepressants and alcohol can enhance the blood pressure lowering effect of this drug. It can also enhance the pressor effect of dihydroergot alkaloids. The simultaneous use of steroid anti-inflammatory drugs can reduce the efficacy of this drug.

Keep away from light and store in sealed container.

5mg

36 months

Shanghai Hengshan Pharmaceutical Co., Ltd.

• Founded in:

  1981-07-20

• Address:

  No. 176, Zidong Road, Minhang District, Shanghai

• Tax NO.:

  91310112132628617W

• Registered Funds:

  47.46 million yuan

• Website:

  Log in to view

• Email:

  Log in to view